•
Found evidence of an association between BCG vaccination and reduced all-cause 28 mortality in TB cases. 29
• Weaker evidence of an association between BCG vaccination and reduced repeat TB 30 episodes in TB cases. 31
• There was little evidence of an association with other TB outcomes. 32
• We explored the identified associations by age and time since vaccination. 33
INTRODUCTION 2
Bacillus Calmette-Guérin (BCG) is one of the mostly widely-used vaccines and the only 3 vaccine that protects against tuberculosis (TB) disease. BCG was first used in humans in 4 1921 and was introduced into the WHO Expanded Program on Immunization in 1974.
[1] 5 BCG vaccination has been controversial due to its variable efficacy and possibility of 6 causing a false positive result with the standard skin test for TB.
[2] However, the lack of a 7 more effective vaccine and the emergence of drug-resistant TB strains means that BCG 8 remains the best available vaccination for TB. 9 BCG's primary mode of action is to directly prevent the development of active, symptomatic 10 disease. Its efficacy in adults is context specific, with estimates ranging between 0% and 11 78%.
[3] Efficacy has been shown to be dependent on previous exposure, with unexposed 12 individuals receiving the greatest benefit.
[4] Unlike in adults, BCG has consistently been 13 shown to be highly protective against TB and TB meningitis in children. [5, 6] For this 14 reason the majority of countries that use BCG vaccinate at birth. [7, 8] Adult vaccination is 15 no longer common in the UK, where universal BCG vaccination of adolescents was stopped 16 in 2005 in favour of a targeted neonatal programme aimed at high risk children. 17
Vaccination policy has been primarily based on reducing the incidence of active TB and 18 little attention has been given to any additional effects of BCG. [9, 10] There is some 19 evidence that BCG vaccination induces innate immune responses which may provide non-20 specific protection,[11] TB patients with BCG scars were found to respond better to 21 treatment with earlier sputum smear conversion, [12] and there is evidence to suggest that 22 BCG vaccination is associated with reduced all-cause neonatal mortality [13, 14] and both 23 reduced TB [15] and all-cause [16] mortality in the general population. Given that the 24 immunology behind TB immunity is not well understood these findings suggest that BCG 25 may play a more important role in improving TB outcomes than previously thought. We 26 aimed to quantify the effects of BCG vaccination on outcomes for individuals with notified 27 TB in England using routinely collected surveillance data to provide evidence for 28 appropriate public health action and provision. Where we found an association, we 29 additionally explored the role of years since vaccination, and age at vaccination. 30 1 METHOD 2
Enhanced Tuberculosis Surveillance (ETS) system 3
We extracted all notifications from the Enhanced Tuberculosis Surveillance (ETS) system 4 from January 1, 2009 to December 31, 2015. BCG vaccination status and year of vaccination 5 have been collected since 2008. We considered five TB outcomes which were selected due 6 to their association with increased case infectiousness or poor consequences for patients 7 (table 1) . 8 Table 1 : Summary of outcome definitions and rationale for inclusion 9
Outcome Definition
All-cause mortality All-cause mortality was defined using the overall outcome recorded in ETS, this is based on follow up at 12, 24, and 36 months (or until treatment completion). If a case dies within 12 months of completing treatment, from TB or from a cause related to TB then their overall outcome will be updated in the ETS. Those that were lost to follow up, or not evaluated were treated as missing. Death due to TB (in those who died)
For cases with a known cause of death, death due to TB is defined as those that died from TB, or where TB had contributed to their death.
Recurrent TB
TB cases who had recurrent episodes were identified in the dataset.
Pulmonary disease
Cases that present with pulmonary TB (regardless of extra-pulmonary TB status).
Sputum smear status -positive
Status of sputum sample tested for Acid-Fast Bacilli.
Exposure variables relating to BCG 10
We included three exposure variables related to BCG: BCG status (vaccinated, yes/no), 11 years since vaccination and age at vaccination. 12 BCG status was taken directly from the ETS. Years since BCG vaccination was defined as 13 year of notification minus year of vaccination and categorised into two groups (0 to 10 and 14 11+ years), based on evidence that the average duration of BCG protection is 10-15 15 years.
[15] Age at vaccination is defined in the online supplementary information. 16
Statistical Analysis 17
R was used for all statistical analysis.
[17] The analysis was conducted in two stages. Firstly, 18 we calculated proportions for all demographic and outcome variables, and compared 19 vaccinated and unvaccinated TB cases using the ! " test. Secondly, we used logistic 20 regression, with complete case analysis, to estimate the association between exposures and 1 outcome variables, both with and without adjustment for confounders. 2
In the multivariable models, we adjusted for sex, [18] [19] [20] the multivariable analysis using multiply imputed data were comparable to those found 12 using complete case analysis, except that there was some evidence that vaccination in 13 adolescence, compared to under 1, was associated with increased, rather than decreased, 14 all-cause mortality (aOR: 1.57 (95% CI 1.13 to 2.19), supplementary table S7). 15
Deaths due to TB (in those who died) 16
There was little evidence of any association between BCG vaccination and deaths due to TB 17 (in those who died and where cause of death was known) in the univariable analysis (table  18 2). The adjusted point estimate indicated an association between BCG vaccination and 19 reduced deaths due to TB (in those who died) although the confidence intervals remained 20 wide with a similar result found using multiply imputed data (see online supplementary  21  table S5 ). There were insufficient data to robustly estimate an association between deaths 22 due to TB (in those who died) and years since vaccination or age at vaccination (table 3,  23  supplementary table S4) . 24
Recurrent TB 25
In both the univariable and multivariable analysis there was some evidence that BCG 26 vaccination was associated with reduced recurrent TB, although the strength of the 27 evidence was weakened after adjusting for confounders (table 2) . In the adjusted analysis, 28 the odds of recurrent TB were lower for BCG vaccinated cases compared to unvaccinated 29 cases, with an aOR of 0.90 (95% CI 0.81 to 1.00, P: 0.056). The strength of the evidence for 30 this association was comparable in the analysis using multiply imputed data (see online 31
supplementary table S5). There was little evidence in the adjusted analysis of any 32 association between recurrent TB and years since vaccination (table 3) or age at  33  vaccination (supplementary table S4 ). 34
Other Outcomes 35
After adjusting for confounders there was little evidence for any association between BCG 36 vaccination and pulmonary disease or positive sputum smear status (table 2) ; similar 37 results were found using multiply imputed data (see online supplementary table S5). 38 Using TB surveillance data collected in England we found that BCG vaccination, prior to the 3 development of active TB, was associated with reduced all-cause mortality and fewer 4 recurrent TB cases, although the evidence for this association was weaker. There was some 5
suggestion that the association with all-cause mortality was due to reduced deaths due to 6 TB (in those who died), though the study was underpowered to definitively assess this. We 7 did not find evidence of an association between BCG status and positive smear status or 8 pulmonary TB. Analysis with multiply imputed data indicated that notification 10+ years 9 after vaccination was associated with increased all-cause mortality. In separate analyses, 10 there was some evidence that vaccination at birth, compared to at any other age, was 11 associated with reduced all-cause mortality, and increased deaths due to TB (in those who 12 died). 13
This study used a large detailed dataset, with coverage across demographic groups, and 14 standardized data collection from notifications and laboratories. Variable data completeness changed with time, with both BCG vaccination status and year 29 of vaccination having a high percentage of missing data, which may not be missing 30 completely at random. We therefore checked the robustness of our results with multiple 31 imputation including regional variability, however an unknown missing not at random 32 mechanism, or unmeasured confounding may still have introduced bias. We found a greatly 33 increased risk of all-cause mortality for those vaccinated more than 10 years ago in the 34 analysis with multiply imputed data, compared to the complete case analysis. This is likely 35 to be driven by a missing not at random mechanism for years since vaccination, with older 36 cases being both more likely to have been vaccinated more than 10 years previously and to 37 also have an unknown year of vaccination. The high percentage of missing data also means 38 that we were likely to be underpowered to detect an effect of BCG vaccination on sputum 39 smear status and deaths due to TB (in those who died), with years since vaccination, and 40 age at vaccination likely to be underpowered for all outcomes. We were not able to adjust 41 for either tuberculin skin test (TST) stringency, or the latitude effect, although we were 42 able to adjust for UK birth status.
[29] However, the bias induced by these confounders is 43 likely to be towards the null, meaning that our effect estimates are likely to be conservative. 44
Finally, BCG vaccination status may be subject to misclassification due to recall bias; 1 validation studies of the recording of BCG status in the ETS would be required to assess 2 this. 3
Little work has been done to assess the overall effect of BCG on outcomes for active TB 4 cases although the possible non-specific effects of BCG are an area of active 5 research. [14, 30, 31] Whilst multiple studies have investigated BCG's association with all-6 cause mortality, it has been difficult to assess whether the association continues beyond 7 the first year of life.
[31] The effect size of the association we identified between BCG and 8 all-cause mortality in active TB cases was comparable to that found in a Danish case-cohort 9 study in the general population (aHR: 0. between BCG vaccination and all-cause mortality or recurrent TB. This study could not 23 determine the possible causal pathway for the association between BCG vaccination all-24 cause mortality, and recurrent TB. These are important to establish in order to understand 25 the effect of BCG vaccination on TB outcomes. 26
We found that BCG vaccination was associated with reduced all-cause mortality, with some 27 weaker evidence of an association with reduced recurrent TB. A plausible mechanism for 28 this association is that BCG vaccination improves treatment outcomes, [12] which then 29 results in decreased mortality, and reduced recurrent TB. However, these effects may also 30 be independent and for all-cause mortality may not be directly related to active TB. In this 31 case, a possible mechanism for the association between BCG vaccination and all-cause 32 mortality is that BCG vaccination modulates the innate immune response, resulting in non-33 specific protection.
[11] For low incidence countries, where the reduction in TB cases has 34 been used as evidence to scale back vaccination programs, [7] these results suggest that 35 BCG vaccination may be more beneficial than previously thought. In countries that target 36 vaccination at those considered to be at high risk of TB the results from this study could be 37 used to help drive uptake by providing additional incentives for vaccination. The evidence 38
we have presented should be considered in future cost-effectiveness studies of BCG 39 vaccination programs. 40
Further work is required to determine whether years since vaccination and age at 41 vaccination are associated with TB outcomes as this study was limited by low sample size, 42 missing data for year of vaccination, and the relative rarity of some TB outcomes. However, 43 due to the continuous collection of the surveillance data used in this analysis, this study 44 could be repeated once additional data have been collected. The results from this study 1 require validation in independent datasets and the analysis should be reproducible in other 2 low incidence countries that have similarly developed surveillance systems. If validated in 3 low incidence countries, similar studies in medium to high incidence countries should be 4 conducted because any effect would have a greater impact in these settings. 5
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